Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration
Clinical trial NCT03764631 · COMPLETED
Trial details
- NCT number
- NCT03764631
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2018-09-26
- Primary completion
- 2021-01-11
- Enrollment
- 1502
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.